ArticleMedicine2026
Impact of the COVID-19 pandemic on diagnosis, treatment, and prognosis of cervical, endometrial, and ovarian cancers: A retrospective cohort study based on the SEER database.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The coronavirus disease 2019 pandemic disrupted healthcare systems worldwide, but population-based evidence on its effects on gynecologic cancer care remains limited. We evaluated changes in diagnosis, disease presentation, treatment timeliness, and cancer-specific survival (CSS) for cervical, endometrial, and ovarian cancers during the pandemic. In this retrospective cohort study, Surveillance, Epidemiology, and End Results (SEER)-22 data were used to evaluate trends in newly diagnosed cases from 2017 to 2021, and SEER-17 data to compare patients diagnosed in 2020 (pandemic cohort) with those diagnosed in 2018 to 2019 (pre-pandemic cohort). Eligible patients were aged 20 to 85 years with primary cervical, endometrial, or ovarian cancer. Demographic characteristics, disease presentation, time from diagnosis to treatment initiation, and CSS were compared using ordinal logistic regression, logistic regression, and Kaplan-Meier/log-rank analyses. The cohorts comprised 7997 patients with cervical, 36,151 with endometrial, and 11,508 with ovarian cancer; median follow-up in the pandemic cohort was 27 to 28 months. In SEER-22, new diagnoses in 2020 decreased by 8.7%, 5.5%, and 6.5% for cervical, endometrial, and ovarian cancers versus 2019. Diagnosis in 2020 was associated with more advanced-stage endometrial cancer (odds ratio, 1.06; 95% confidence interval [CI], 1.01-1.12; P = .027) but not cervical or ovarian cancer. Median time from diagnosis to treatment was shorter in the pandemic cohort for cervical (28 vs 30 days; P = .019) and endometrial cancer (28 vs 31 days; P < .001), but not for ovarian cancer (6 vs 4 days; P = .127). The pandemic cohort had borderline worse CSS for cervical cancer (hazard ratio [HR], 1.11; 95% CI, 1.00-1.24; P = .050) and worse CSS for endometrial cancer (HR, 1.10; 95% CI, 1.02-1.18; P = .009), but not ovarian cancer (HR, 1.05; 95% CI, 0.98-1.14; P = .185); 18-month CSS rates (pre-pandemic vs pandemic) were 86.6% vs 84.5%, 93.1% vs 92.6%, and 82.8% vs 83.0%. The pandemic period was associated with fewer recorded diagnoses of the 3 major gynecologic cancers, a modest shift toward more advanced-stage endometrial cancer, and worse short-term CSS for cervical and endometrial cancers. The reduction in recorded diagnoses may reflect disrupted screening and delayed presentation rather than a true decline in cancer occurrence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.